Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy DOI Creative Commons
Fotios Mpekris, Myrofora Panagi, Antonia Charalambous

et al.

Cell Reports Medicine, Journal Year: 2024, Volume and Issue: 5(7), P. 101626 - 101626

Published: June 28, 2024

Solid tumor pathology, characterized by abnormalities in the microenvironment (TME), challenges therapeutic effectiveness. Mechanical factors, including increased stiffness and accumulation of intratumoral forces, can determine success cancer treatments, defining tumor's "mechanopathology" profile. These cause extensive vascular compression, leading to hypoperfusion hypoxia. Hypoperfusion hinders drug delivery, while hypoxia creates an unfavorable TME, promoting progression through immunosuppression, heightened metastatic potential, resistance, chaotic angiogenesis. Strategies targeting TME mechanopathology, such as stroma normalization, hold promise enhancing therapies with some already advancing clinic. Normalization be achieved using anti-angiogenic agents, mechanotherapeutics, immune checkpoint inhibitors, engineered bacterial therapeutics, metronomic nanomedicine, ultrasound sonopermeation. Here, we review methods developed rectify which have even led cures preclinical models, discuss their bench-to-bedside translation, derivation biomarkers from mechanopathology for personalized therapy.

Language: Английский

The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment DOI Creative Commons
Seong Keun Kim, Sun Wook Cho

Frontiers in Pharmacology, Journal Year: 2022, Volume and Issue: 13

Published: May 24, 2022

Recently, in the field of cancer treatment, paradigm has changed to immunotherapy that activates immune system induce attacks. Among them, checkpoint inhibitors (ICI) are attracting attention as excellent and continuous clinical results. However, it shows not only limitations such efficacy some patients or indications, but also side-effects resistance occur. Therefore, is necessary understand factors tumor microenvironment (TME) affect immunotherapy, is, mechanism by which grows while evading suppressing attacks from within TME. Tumors can evade through various mechanisms restricting antigen recognition, inhibiting system, inducing T cell exhaustion. In addition, tumors inhibit accumulating specific metabolites signal TME limiting nutrients available cells. order overcome develop effective treatments therapeutic strategies, an approach needed functions cells integrated manner based on this review, we will examine effects cells, especially how anti-cancer strategies

Language: Английский

Citations

271
The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy DOI Open Access
Yanlin Yu

Cancers, Journal Year: 2023, Volume and Issue: 15(8), P. 2323 - 2323

Published: April 16, 2023

Metastatic tumors cause the most deaths in cancer patients. Treating metastasis remains primary goal of current research. Although immune system prevents and kills tumor cells, function metastatic has been unappreciated for decades because are able to develop complex signaling pathways suppress responses, leading them escape detection elimination. Studies showed NK cell-based therapies have many advantages promise fighting cancers. We here review progression, specifically focusing on ability cells antimetastasis, how cell attack, as well recent development effective antimetastatic immunotherapies.

Language: Английский

Citations

55
Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities DOI Creative Commons
Mona Meng Wang, Sarah E. Coupland, Tero Aittokallio

et al.

British Journal of Cancer, Journal Year: 2023, Volume and Issue: 129(8), P. 1212 - 1224

Published: July 15, 2023

Abstract Immune checkpoint therapies (ICT) can reinvigorate the effector functions of anti-tumour T cells, improving cancer patient outcomes. Anti-tumour cells are initially formed during their first contact (priming) with tumour antigens by antigen-presenting (APCs). Unfortunately, many patients refractory to ICT because tumours considered be ‘cold’ tumours—i.e., they do not allow generation (so-called ‘desert’ tumours) or infiltration existing (T-cell-excluded tumours). Desert disturb antigen processing and priming targeting APCs suppressive factors derived from genetic instabilities. In contrast, T-cell-excluded characterised blocking effective lymphocytes infiltrating masses obstacles, such as fibrosis tumour-cell-induced immunosuppression. This review delves into critical mechanisms which induce T-cell ‘desertification’ ‘exclusion’ in tumours. Filling gaps our knowledge regarding these pro-tumoral will aid researchers developing novel class immunotherapies that aim at restoring more efficient leukocyte trafficking. Such developments expected unleash clinical benefit patients.

Language: Английский

Citations

48
Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment DOI Open Access
Juan Carlos Restrepo,

Diana Dueñas,

Zuray Corredor

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(13), P. 3474 - 3474

Published: July 3, 2023

Non-small cell lung cancer (NSCLC) is a significant public health concern with high mortality rates. Recent advancements in genomic data, bioinformatics tools, and the utilization of biomarkers have improved possibilities for early diagnosis, effective treatment, follow-up NSCLC. Biomarkers play crucial role precision medicine by providing measurable indicators disease characteristics, enabling tailored treatment strategies. The integration big data artificial intelligence (AI) further enhances potential personalized through advanced biomarker analysis. However, challenges remain impact new on efficacy due to limited evidence. Data analysis, interpretation, adoption approaches clinical practice pose additional emphasize technologies such as analysis (AI), which enhance Despite these obstacles, into has shown promising results NSCLC, improving patient outcomes targeted therapies. Continued research discovery, utilization, evidence generation are necessary overcome medicine. Addressing obstacles will contribute continued improvement non-small cancer.

Language: Английский

Citations

47
Cancer Nanovaccines: Nanomaterials and Clinical Perspectives DOI
Nimeet Desai, Vivek P. Chavda, Thakur Raghu Raj Singh

et al.

Small, Journal Year: 2024, Volume and Issue: 20(35)

Published: May 1, 2024

Abstract Cancer nanovaccines represent a promising frontier in cancer immunotherapy, utilizing nanotechnology to augment traditional vaccine efficacy. This review comprehensively examines the current state‐of‐the‐art nanovaccine development, elucidating innovative strategies and technologies employed their design. It explores both preclinical clinical advancements, emphasizing key studies demonstrating potential elicit robust anti‐tumor immune responses. The study encompasses various facets, including integrating biomaterial‐based nanocarriers for antigen delivery, adjuvant selection, impact of nanoscale properties on performance. Detailed insights into complex interplay between tumor microenvironment responses are provided, highlighting challenges opportunities optimizing therapeutic outcomes. Additionally, presents thorough analysis ongoing trials, presenting snapshot landscape. By curating latest scientific findings developments, this aims serve as comprehensive resource researchers clinicians engaged advancing immunotherapy. Integrating design holds immense promise revolutionizing treatment paradigms, provides timely update evolving landscape nanovaccines.

Language: Английский

Citations

26
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition DOI Creative Commons
Antonino Glaviano,

Hannah Lau,

Lukas M. Carter

et al.

Journal of Hematology & Oncology, Journal Year: 2025, Volume and Issue: 18(1)

Published: Jan. 13, 2025

The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, signaling molecules that interact promote growth therapeutic resistance. Elucidating the intricate interactions between cells TME crucial in understanding progression challenges. A critical process induced by epithelial-mesenchymal transition (EMT), wherein epithelial acquire mesenchymal traits, which enhance their motility invasiveness progression. By targeting various components TME, novel investigational strategies aim disrupt TME's contribution EMT, thereby improving efficacy, addressing resistance, offering a nuanced approach therapy. This review scrutinizes key players emphasizing avenues therapeutically components. Moreover, article discusses implications for resistance mechanisms highlights current toward modulation along with potential caveats.

Language: Английский

Citations

16
Succinate Nanomaterials Boost Tumor Immunotherapy via Activating Cell Pyroptosis and Enhancing MHC-I Expression DOI Creative Commons
Pan Zheng, Guanglei Wang, Bin Liu

et al.

Journal of the American Chemical Society, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 2, 2025

Despite the promising clinical applications of immunotherapy, its effectiveness is often limited by low immune responses and tumor escape. In this study, we introduce a simple drug-free inorganic nanomaterial, sodium succinate (C4H4Na2O4 NPs), prepared using rapid microemulsion method to enhance cancer immunotherapy. The synthesized C4H4Na2O4 NPs can release high concentrations Na+ ions into cells, leading an increase in intracellular osmolarity. This triggers pyroptosis pathway, resulting cellular contents, inflammatory factors, damage-associated molecular patterns, which ultimately boost responses. Furthermore, inhibit escape through upregulating major histocompatibility complex-I (MHC-I) expression. Collectively, significantly growth metastasis pyroptosis-induced activation MHC-I expression upregulation-remitted research offers novel approach treatment that leverages pyroptosis, demonstrating potential for application

Language: Английский

Citations

4
Brd7 loss reawakens dormant metastasis initiating cells in lung by forging an immunosuppressive niche DOI Creative Commons
Jayanta Mondal, Junfeng Zhang,

Qing Feng

et al.

Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 5, 2025

Metastasis in cancer is influenced by epigenetic factors. Using an vivo screen, we demonstrate that several subunits of the polybromo-associated BAF (PBAF) chromatin remodeling complex, particularly Brd7, are required for maintaining breast metastatic dormancy lungs female mice. Brd7 loss induces reawakening, along with modifications epigenomic landscapes and upregulated oncogenic signaling. Breast cells harboring inactivation also reprogram surrounding immune microenvironment downregulating MHC-1 expression promoting a pro-metastatic cytokine profile. Flow cytometric single-cell analyses reveal increased levels pro-tumorigenic inflammatory transitional neutrophils, CD8+ exhausted T cells, CD4+ stress response from mice Brd7-deficient metastases. Finally, attenuating this immunosuppressive milieu neutrophil depletion, extracellular trap (NET) inhibition, or checkpoint therapy abrogates outgrowth. These findings implicate PBAF triggering outgrowth cancer, pointing to targetable underlying mechanisms involving specific cell compartments. Metastasis-initiating can reawaken dormant state initially allowed them survive, Here, authors show promotes tumor drives reawakening lung.

Language: Английский

Citations

2
Tumor secretome shapes the immune landscape during cancer progression DOI Creative Commons
Jianqiang Yang, Sijia Tang, Nabil F. Saba

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2025, Volume and Issue: 44(1)

Published: Feb. 10, 2025

Language: Английский

Citations

2
Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence DOI Creative Commons
Muhammad Tufail, Canhua Jiang, Ning Li

et al.

Military Medical Research, Journal Year: 2025, Volume and Issue: 12(1)

Published: Feb. 11, 2025

Abstract Cancer recurrence, driven by the phenomenon of tumor dormancy, presents a formidable challenge in oncology. Dormant cancer cells have ability to evade detection and treatment, leading relapse. This review emphasizes urgent need comprehend dormancy its implications for recurrence. Despite notable advancements, significant gaps remain our understanding mechanisms underlying lack reliable biomarkers predicting provides comprehensive analysis cellular, angiogenic, immunological aspects dormancy. It highlights current therapeutic strategies targeting dormant cells, particularly combination therapies immunotherapies, which hold promise preventing By elucidating these proposing innovative research methodologies, this aims deepen ultimately facilitating development more effective recurrence improving patient outcomes.

Language: Английский

Citations

2